|BIQLF -- USA Stock|| |
USD 6.28 0.88 16.30%
Mr. Ian Roy Johnson was appointed as NonExecutive Chairman of the Board of the Company, effective 10 June, 2016. Mr Johnson has spent his career working in a number of Life Sciences companies and is currently nonexecutive chairman of Cyprotex PLC and was formerly nonexecutive chairman of Celsis International Group as well as a nonexecutive director of MyCelx Technologies Corporationrationration.
Age: 62 Chairman Since 2016
44 1264 835 835 http://www.bioquellplc.com
The company has return on total asset (ROA)
of 5.58 %
which means that it generated profit of $5.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 10.64 %
meaning that it generated $10.64 on every $100 dollars invested by stockholders.
Bioquell plc designs, manufactures, and supplies bio-decontamination and containment equipment, and related products and services in the United Kingdom and internationally. The company was incorporated in 1925 and is headquartered in Andover, the United Kingdom. Bioquell plc operates under Medical Devices classification in USA and traded on OTC Market. It employs 220 people.Bioquell plc (BIQLF) is traded on OTC Market in USA. It is located in 52 Royce Close and employs 220 people.
Bioquell plc Leadership Team
|Ian Johnson, Non-Executive Chairman of the Board|
|Nigel Keen, Independent Non-Executive Chairman of the Board|
|Nicholas Adams, Group Chief Executive and Executive Director|
|Christopher Mills, Non-Executive Director|
|Anthony Bourne, Independent Non-Executive Director|
|Georgina Pope, Company Secretary|
|Michael Roller, Group Finance Director, Director|
|Ian Carruthers, Independent Non-Executive Director|
|Simon Constantine, Independent Non-Executive Director|
Stock Performance Indicators